# BTG4

## Overview
BTG4 is a gene that encodes the BTG anti-proliferation factor 4, a protein belonging to the BTG/Tob family, which is known for its role in regulating cell cycle progression and mRNA stability. The BTG4 protein is characterized by a conserved N-terminal BTG domain, which facilitates protein-protein interactions, particularly with components of the CCR4-NOT complex involved in mRNA deadenylation (Winkler2009The; Pasternak2016The). This protein is crucial in processes such as oocyte maturation, where it helps maintain metaphase II arrest by regulating maternal mRNA stability (Pasternak2016The). BTG4's function extends to influencing cell cycle arrest and apoptosis, with implications in various physiological and pathological contexts, including cancer and inflammatory diseases (Fonseca‐Camarillo2021Expression; Mauxion2009BTGTOB). The gene's expression and activity are of particular interest in the study of chronic lymphocytic leukemia and ulcerative colitis, where it may play a role in disease progression and inflammatory response (Fonseca‐Camarillo2021Expression; Auer2005Identification).

## Structure
BTG4 is a member of the BTG/Tob protein family, characterized by a conserved N-terminal domain known as the BTG domain, which spans 104-106 amino acids and functions as a protein-protein interaction module (Winkler2009The). This domain is capable of binding to DNA-binding transcription factors and components of the Ccr4-Not complex, such as CNOT7 and CNOT8, which are deadenylase subunits (Winkler2009The; Pasternak2016The). The BTG domain contains two highly conserved regions, Box A and Box B (Winkler2009The). 

The C-terminal regions of BTG4 are less conserved compared to the N-terminal domain, allowing for unique protein-protein interactions specific to each family member (Winkler2009The). BTG4 is involved in mRNA deadenylation, particularly in oocyte maturation, where it interacts with the CCR4-NOT complex to regulate mRNA stability (Pasternak2016The). 

While specific details about the tertiary or quaternary structure of BTG4 are not provided, the protein's interactions and functional roles suggest a complex involvement in cellular processes. There is no detailed information on post-translational modifications or splice variant isoforms for BTG4 in the provided context.

## Function
BTG4, a member of the BTG/Tob protein family, plays a significant role in regulating cell cycle progression and proliferation. It is involved in the arrest of the G1 phase of the cell cycle, thereby inhibiting the transition to the S phase, which is crucial for DNA replication and cell division (Fonseca‐Camarillo2021Expression; Winkler2009The). This function is mediated through its interactions with DNA-binding transcription factors and components of the Ccr4-Not complex, such as CNOT7 and CNOT8, which are involved in mRNA deadenylation and turnover (Winkler2009The).

BTG4 is active in both the cytoplasm and nucleus, where it influences mRNA stability and translation, contributing to its role in cell cycle regulation and apoptosis (Winkler2009The). The protein is characterized by a conserved N-terminal BTG domain, which serves as a protein-protein interaction module, facilitating its involvement in transcription regulation and mRNA turnover (Winkler2009The). In the context of inflammatory processes, BTG4 expression is increased in active ulcerative colitis, suggesting a role in modulating the inflammatory response by inhibiting cell proliferation and activating immune cells (Fonseca‐Camarillo2021Expression).

## Clinical Significance
BTG4, a member of the BTG/TOB family of antiproliferative proteins, plays a significant role in various diseases due to its involvement in cell cycle regulation and apoptosis. In chronic lymphocytic leukemia (CLL), BTG4 is implicated in the pathogenesis associated with deletions at the 11q23 chromosomal region. These deletions are linked to progressive disease and poor prognosis. The inactivation of BTG4 through haploinsufficiency may contribute to CLL pathogenesis, although specific mutations in BTG4 were not identified in the coding sequences of CLL patients (Auer2005Identification).

In the context of inflammatory bowel disease (IBD), BTG4 expression is notably increased in patients with active ulcerative colitis (UC) compared to those in remission and controls without inflammation. This suggests a role for BTG4 in the inflammatory response, potentially acting as a compensatory mechanism to regulate inflammation and maintain homeostasis (Fonseca‐Camarillo2021Expression).

BTG4's involvement in cancer is also highlighted by its altered expression in various malignancies, where it may exert antiproliferative effects through interactions with the deadenylase complex, impacting posttranscriptional regulation of gene expression (Mauxion2009BTGTOB).

## Interactions
BTG4, a member of the BTG/Tob protein family, is involved in several critical protein interactions that regulate mRNA deadenylation and cell cycle progression. BTG4 interacts with the CCR4-NOT deadenylase complex, specifically with the CNOT7 and CNOT8 subunits, which are essential for the deadenylation of maternal mRNAs during metaphase II arrest in oocytes (Pasternak2016The). This interaction is crucial for preventing the spontaneous activation of eggs by maintaining metaphase II arrest (Pasternak2016The).

The interaction between BTG4 and the CCR4-NOT complex is facilitated by the BTG4 protein's APRO domain. A mutation in this domain (W95A) disrupts the interaction with CNOT7 and CNOT8, highlighting the importance of this domain for BTG4's function (Pasternak2016The). BTG4 also interacts with PABPN1, a poly(A)-binding protein, which aids in recruiting the CCR4-NOT complex to target mRNAs, although this interaction has not been confirmed in vivo (Pasternak2016The).

Unlike other BTG/Tob family members, BTG4 does not interact with PRMT1, indicating a divergence in interaction partners within the family (Amine2021A). These interactions underscore BTG4's role in regulating mRNA stability and translation during oocyte maturation.


## References


[1. (Auer2005Identification) Rebecca L. Auer, Jane Starczynski, Suzanne McElwaine, Francesco Bertoni, Adrian C. Newland, Chris D. Fegan, and Finbarr E. Cotter. Identification of a potential role forpou2af1 andbtg4 in the deletion of 11q23 in chronic lymphocytic leukemia. Genes, Chromosomes and Cancer, 43(1):1–10, 2005. URL: http://dx.doi.org/10.1002/gcc.20159, doi:10.1002/gcc.20159. This article has 28 citations.](https://doi.org/10.1002/gcc.20159)

[2. (Amine2021A) Hamza Amine, Nina Ripin, Sahil Sharma, Georg Stoecklin, Frédéric H Allain, Bertrand Séraphin, and Fabienne Mauxion. A conserved motif in human btg1 and btg2 proteins mediates interaction with the poly(a) binding protein pabpc1 to stimulate mrna deadenylation. RNA Biology, 18(12):2450–2465, June 2021. URL: http://dx.doi.org/10.1080/15476286.2021.1925476, doi:10.1080/15476286.2021.1925476. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/15476286.2021.1925476)

[3. (Winkler2009The) G. Sebastiaan Winkler. The mammalian anti‐proliferative btg/tob protein family. Journal of Cellular Physiology, 222(1):66–72, September 2009. URL: http://dx.doi.org/10.1002/jcp.21919, doi:10.1002/jcp.21919. This article has 242 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.21919)

[4. (Pasternak2016The) Michał Pasternak, Sybille Pfender, Balaji Santhanam, and Melina Schuh. The btg4 and caf1 complex prevents the spontaneous activation of eggs by deadenylating maternal mrnas. Open Biology, 6(9):160184, September 2016. URL: http://dx.doi.org/10.1098/rsob.160184, doi:10.1098/rsob.160184. This article has 47 citations and is from a peer-reviewed journal.](https://doi.org/10.1098/rsob.160184)

[5. (Mauxion2009BTGTOB) Fabienne Mauxion, Chyi-Ying A. Chen, Bertrand Séraphin, and Ann-Bin Shyu. Btg/tob factors impact deadenylases. Trends in Biochemical Sciences, 34(12):640–647, December 2009. URL: http://dx.doi.org/10.1016/j.tibs.2009.07.008, doi:10.1016/j.tibs.2009.07.008. This article has 76 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tibs.2009.07.008)

[6. (Fonseca‐Camarillo2021Expression) Gabriela Fonseca‐Camarillo, Janette Furuzawa‐Carballeda, Ángel A. Priego‐Ranero, Braulio Martínez‐Benítez, Rafael Barreto‐Zúñiga, and Jesús K. Yamamoto‐Furusho. Expression of tob/btg family members in patients with inflammatory bowel disease. Scandinavian Journal of Immunology, January 2021. URL: http://dx.doi.org/10.1111/sji.13004, doi:10.1111/sji.13004. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/sji.13004)